GlaxoSmithKline plc (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 156   

Articles published

GSK 40.98 +0.28 (0.69%)
price chart
Is GlaxoSmithKline plc (ADR) (GSK) A Good Stock To Buy?
At the end of this article, we will also compare GlaxoSmithKline plc (ADR) (NYSE:GSK) to other stocks including NIKE, Inc. (NYSE:NKE), Lloyds Banking Group PLC (ADR) (NYSE:LYG), and BHP Billiton plc (ADR) (NYSE:BBL) to get a better sense of its ...
What's Propelling GlaxoSmithKline plc (ADR) to Increase So Much? The ...
Three Stocks on Trader's Radar: GlaxoSmithKline plc (ADR)(GSK), Medical ...  Investor Wired
Is The Proposed GlaxoSmithKline plc (ADR) Split Wise?
GlaxoSmithKline plc (ADR) (NYSE:GSK) may be in for some major restructuring. Neil Woodford, a veteran UK fund manager who holds the company in his equity income fund, is calling for a four-way split of GSK's operations, as per a latest report.
GlaxoSmithKline plc (ADR) (GSK): Stock Surges Post-Earnings  Business Finance News
GlaxoSmithKline plc (ADR) (GSK) Gets the Much Needed Boost to Deliver Better ...  InvestCorrectly
GlaxoSmithKline plc (ADR) (GSK) Stock Update: Mixed Signals For Investors
GlaxoSmithKline Plc (ADR) (NYSE:GSK) stock has performed moderately well so far this year, marked with some steep increases and declines as well.
GlaxoSmithKline plc (ADR) Stock Update: Drug-Maker In Hot Water Again
British pharmaceutical giant GlaxoSmithKline Plc (ADR) (NYSE:GSK) has seen a gloomy stock performance so far this year, with only a few steep increases barely able to offset the many declines.
GlaxoSmithKline plc (ADR): Why Nucala's FDA Approval Is Significant
GlaxoSmithKline plc (ADR) (NYSE:GSK) bagged the Food and Drug Administration approval on Wednesday for its latest respiratory medicine, Nucala, to treat severe asthma in combination with other drugs.
Should Gilead Sciences, Inc. Fear GlaxoSmithKline plc (ADR)?
Gilead Sciences, Inc. (NASDAQ:GILD) and GlaxoSmithKline plc (ADR) (NYSE:GSK) seem to be battling for a larger share of the HIV market.
Is GlaxoSmithKline plc (ADR) On The Path To Recovery?
GlaxoSmithKline Plc ADR (NYSE:GSK) announced its five-year growth plans, intended to reinstate investors' trust in the drug maker.
GlaxoSmithKline plc (ADR) (GSK) Stock Update - Takeover Rumors Drive Recent Gain
GlaxoSmithKline plc. (ADR) (NYSE:GSK) stock has gone up 7.48% since the release of its higher-than-expected second quarter fiscal '15 (2QFY15) earnings on July 29.
GlaxoSmithKline plc (ADR) (NYSE:GSK) Cautious After Legionnaire Bug Found in ...  Wall Street Observer
Better Dividend Stock: GlaxoSmithKline plc vs. AstraZeneca plc  Motley Fool
European Equities for Your Trading Radar: GlaxoSmithKline plc (ADR) (GSK ...
European stocks moved higher and oil prices reversed course and fell 1 percent on Wednesday as investors' concerns eased over the potential fallout of Turkey's shooting down of a Russian fighter jet.
Here's how GlaxoSmithKline plc (ADR) Hopes To Trump Gilead Sciences In HIV Market
GlaxoSmithKline plc (ADR) (NYSE:GSK) has been facing a very troubled pharmaceutical business over the last few years.